Corcept Therapeutics Incorporated
CORT
$71.64
$1.181.67%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 685.45M | 675.04M | 628.56M | 569.61M | 523.53M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 685.45M | 675.04M | 628.56M | 569.61M | 523.53M |
| Cost of Revenue | 10.25M | 9.88M | 8.80M | 7.58M | 7.13M |
| Gross Profit | 675.20M | 665.16M | 619.75M | 562.03M | 516.40M |
| SG&A Expenses | 314.71M | 280.32M | 244.10M | 215.62M | 191.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 574.08M | 537.09M | 484.20M | 440.67M | 401.10M |
| Operating Income | 111.37M | 137.95M | 144.36M | 128.94M | 122.43M |
| Income Before Tax | 136.12M | 161.49M | 166.34M | 149.78M | 141.12M |
| Income Tax Expenses | 2.12M | 20.28M | 24.52M | 23.80M | 23.09M |
| Earnings from Continuing Operations | 133.99 | 141.21 | 141.82 | 125.98 | 118.02 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 133.99M | 141.21M | 141.82M | 125.98M | 118.02M |
| EBIT | 111.37M | 137.95M | 144.36M | 128.94M | 122.43M |
| EBITDA | 112.33M | 138.75M | 145.09M | 129.58M | 123.30M |
| EPS Basic | 1.28 | 1.35 | 1.36 | 1.22 | 1.15 |
| Normalized Basic EPS | 0.83 | 0.98 | 1.02 | 0.92 | 0.87 |
| EPS Diluted | 1.16 | 1.24 | 1.26 | 1.13 | 1.06 |
| Normalized Diluted EPS | 0.75 | 0.90 | 0.94 | 0.85 | 0.80 |
| Average Basic Shares Outstanding | 414.24M | 412.92M | 411.74M | 410.38M | 409.22M |
| Average Diluted Shares Outstanding | 463.25M | 453.34M | 445.77M | 443.14M | 441.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |